{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:08:32Z","timestamp":1780664912889,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["16K09598"],"award-info":[{"award-number":["16K09598"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["17K10617"],"award-info":[{"award-number":["17K10617"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["18K15937"],"award-info":[{"award-number":["18K15937"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10495-020-01612-6","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T18:03:32Z","timestamp":1590689012000},"page":"535-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Combination of a p53-activating CP-31398 and an MDM2 or a FAK inhibitor produces growth suppressive effects in mesothelioma with wild-type p53 genotype"],"prefix":"10.1007","volume":"25","author":[{"given":"Boya","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Shingyoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Hanazono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Thanh","family":"Nguy\u1ec5n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"1612_CR1","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/cncr.22552","volume":"109","author":"AY Lee","year":"2007","unstructured":"Lee AY, Raz DJ, He B et al (2007) Update on the molecular biology of malignant mesothelioma. Cancer 109:1454\u20131461","journal-title":"Cancer"},{"key":"1612_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MCP.0000000000000489","volume":"24","author":"D Katzman","year":"2018","unstructured":"Katzman D, Sterman DH (2018) Updates in the diagnosis and treatment of malignant pleural mesothelioma. Curr Opin Pulm Med 24:319\u2013326","journal-title":"Curr Opin Pulm Med"},{"key":"1612_CR3","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","volume":"75","author":"G Guo","year":"2015","unstructured":"Guo G, Chmielecki J, Goparaju C et al (2015) Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res 75:264\u2013269","journal-title":"Cancer Res"},{"key":"1612_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD et al (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48:407\u2013416","journal-title":"Nat Genet"},{"key":"1612_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13046-018-0850-z","volume":"37","author":"J Shen","year":"2018","unstructured":"Shen J, Cao B, Wang Y et al (2018) Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1\/FAK signalling in breast cancer. J Exp Clin Cancer Res 37:175. https:\/\/doi.org\/10.1186\/s13046-018-0850-z","journal-title":"J Exp Clin Cancer Res"},{"key":"1612_CR6","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1126\/science.286.5449.2507","volume":"286","author":"BA Foster","year":"1999","unstructured":"Foster BA, Coffey HA, Morin MJ et al (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507\u20132510","journal-title":"Science"},{"key":"1612_CR7","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1172\/JCI32481","volume":"117","author":"X Tang","year":"2007","unstructured":"Tang X, Zhu Y, Han L et al (2007) CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 117:3753\u20133764","journal-title":"J Clin Invest"},{"key":"1612_CR8","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/sj.onc.1205362","volume":"21","author":"TM Rippin","year":"2002","unstructured":"Rippin TM, Bykov VJ, Freund SM et al (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119\u20132129","journal-title":"Oncogene"},{"key":"1612_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4161\/cbt.1.1.41","volume":"1","author":"R Takimoto","year":"2002","unstructured":"Takimoto R, Wang W, Dicker DT et al (2002) The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 1:47\u201355","journal-title":"Cancer Biol Ther"},{"key":"1612_CR10","doi-asserted-by":"publisher","first-page":"45887","DOI":"10.1074\/jbc.M401854200","volume":"279","author":"MJ Demma","year":"2004","unstructured":"Demma MJ, Wong S, Maxwell E et al (2004) CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73. J Biol Chem 279:45887\u201345896","journal-title":"J Biol Chem"},{"key":"1612_CR11","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1093\/jnci\/djp355","volume":"101","author":"T Van Maerken","year":"2009","unstructured":"Van Maerken T, Ferdinande L, Taildeman J et al (2009) Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst 101:1562\u20131574","journal-title":"J Natl Cancer Inst"},{"key":"1612_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1593\/neo.06148","volume":"8","author":"S Hopkins-Donaldson","year":"2006","unstructured":"Hopkins-Donaldson S, Belyanskaya LL, Sim\u00f5es-W\u00fcst AP et al (2006) p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia 8:551\u2013559","journal-title":"Neoplasia"},{"key":"1612_CR13","first-page":"237","volume":"6","author":"IM Shapiro","year":"2014","unstructured":"Shapiro IM, Kolev VN, Vidal CM et al (2014) Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med 6:237\u2013268","journal-title":"Sci Transl Med"},{"key":"1612_CR14","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","volume":"27","author":"JC Soria","year":"2016","unstructured":"Soria JC, Gan HK, Blagden SP et al (2016) A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol 27:2268\u20132274","journal-title":"Ann Oncol"},{"key":"1612_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molcel.2007.11.031","volume":"29","author":"ST Lim","year":"2008","unstructured":"Lim ST, Chen XL, Lim Y et al (2008) Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell 29:9\u201322","journal-title":"Mol Cell"},{"key":"1612_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.molonc.2014.08.005","volume":"9","author":"S Ammoun","year":"2015","unstructured":"Ammoun S, Schmid MC, Zhou L et al (2015) The p53\/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours. Mol Oncol 9:236\u2013248","journal-title":"Mol Oncol"},{"key":"1612_CR17","doi-asserted-by":"publisher","first-page":"25008","DOI":"10.1074\/jbc.M414172200","volume":"280","author":"VM Golubovskaya","year":"2005","unstructured":"Golubovskaya VM, Finch R, Cance WG (2005) Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53. J Biol Chem 280:25008\u201325021","journal-title":"J Biol Chem"},{"key":"1612_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/mc.20395","volume":"47","author":"VM Golubovskaya","year":"2008","unstructured":"Golubovskaya VM, Finch R, Kweh F et al (2008) p53 regulates FAK expression in human tumor cells. Mol Carcinog 47:373\u2013382","journal-title":"Mol Carcinog"},{"key":"1612_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1349-7006.2006.00163.x","volume":"97","author":"E Nakataki","year":"2006","unstructured":"Nakataki E, Yano S, Matsumori Y et al (2006) Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci 97:183\u2013191","journal-title":"Cancer Sci"},{"key":"1612_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4161\/cc.27546","volume":"13","author":"D Di Marzo","year":"2014","unstructured":"Di Marzo D, Forte IM, Indovina P et al (2014) Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle 13:652\u2013665","journal-title":"Cell Cycle"},{"key":"1612_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10495-012-0790-6","volume":"18","author":"C Fiorini","year":"2013","unstructured":"Fiorini C, Menegazzi M, Padroni C et al (2013) Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. Apoptosis 18:337\u2013346","journal-title":"Apoptosis"},{"key":"1612_CR22","doi-asserted-by":"publisher","first-page":"10438","DOI":"10.1038\/ncomms10438","volume":"7","author":"S Llanos","year":"2016","unstructured":"Llanos S, Garc\u00eda-Pedrero JM, Morgado-Palacin L et al (2016) Stabilization of p21 by mTORC1\/4E-BP1 predicts clinical outcome of head and neck cancers. Nat Commun 7:10438. https:\/\/doi.org\/10.1038\/ncomms10438","journal-title":"Nat Commun"},{"key":"1612_CR23","first-page":"S55","volume":"2","author":"W Wang","year":"2003","unstructured":"Wang W, Rastinejad F, El-Deiry WS (2003) Restoring p53-dependent tumor suppression. Cancer Biol Ther 2:S55\u2013S63","journal-title":"Cancer Biol Ther"},{"key":"1612_CR24","doi-asserted-by":"publisher","first-page":"6376","DOI":"10.1158\/1078-0432.CCR-08-1526","volume":"14","author":"EA Bassett","year":"2008","unstructured":"Bassett EA, Wang W, Rastinejad F et al (2008) Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res 14:6376\u20136386","journal-title":"Clin Cancer Res"},{"key":"1612_CR25","doi-asserted-by":"publisher","first-page":"26130","DOI":"10.18632\/oncotarget.25452","volume":"9","author":"K Chai","year":"2018","unstructured":"Chai K, Ning X, Nguy\u1ec5n TT et al (2018) Heat shock protein 90 inhibitors augmented endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity. Oncotarget 9:26130\u201326143","journal-title":"Oncotarget"},{"key":"1612_CR26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1006\/excr.2002.5526","volume":"276","author":"Y Luu","year":"2002","unstructured":"Luu Y, Bush J, Cheung KJ Jr et al (2002) The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax\/mitochondrial\/caspase-9 pathway. Exp Cell Res 276:214\u2013222","journal-title":"Exp Cell Res"},{"key":"1612_CR27","first-page":"79","volume":"9","author":"B Zhong","year":"2019","unstructured":"Zhong B, Shingyoji M, Hanazono M et al (2019) A p53-stabilizing agent, CP-31398, induces p21 expression with increased G2\/M phase through the YY1 transcription factor in esophageal carcinoma defective of the p53 pathway. Am J Cancer Res 9:79\u201393","journal-title":"Am J Cancer Res"},{"key":"1612_CR28","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1038\/bjc.2014.165","volume":"110","author":"HE Boudreau","year":"2014","unstructured":"Boudreau HE, Casterline BW, Burke DJ et al (2014) Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-\u03b2-mediated migration of human lung and breast epithelial cells. Br J Cancer 110:2569\u20132582","journal-title":"Br J Cancer"},{"key":"1612_CR29","doi-asserted-by":"publisher","first-page":"e1012976","DOI":"10.1080\/23723556.2015.1012976","volume":"2","author":"G Manic","year":"2015","unstructured":"Manic G, Obrist F, Sistigu A et al (2015) Trial watch: targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. Mol Cell Oncol 2:e1012976","journal-title":"Mol Cell Oncol"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-020-01612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-020-01612-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-020-01612-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:27:29Z","timestamp":1622161649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-020-01612-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":29,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1612"],"URL":"https:\/\/doi.org\/10.1007\/s10495-020-01612-6","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"28 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interests in this research. We obtained a grant from Nichias Corporation. It is not a pharmaceutical company but a company making industrial products for building, automobiles and pipes (see ). The grant is as a kind of their m\u00e9c\u00e9nat activities, corporate social contributions, which is aimed to assist for medical research for intractable cancer treatments. We are thereby irrelevant to any employment, consultancy, patents or products in development or marketed products to the company. All the authors agree to publish the data included in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict interests"}}]}}